Company Overview of Ritter Pharmaceuticals, Inc.
Ritter Pharmaceuticals, Inc. develops and sells novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which has completed Phase 2b clinical trial for the reduction of symptoms associated with lactose intolerance. The company’s product, RP-G28 is designed to stimulate the growth of lactose-metabolizing bacteria in the colon, thereby adapting the gut microbiome to assist in digesting the lactose that reaches the large intestine. The company was formerly known as Ritter Natural Sciences, LLC and changed its name to Ritter Pharmaceuticals, Inc. in September 2008. Ritter Pharmaceuti...
1880 Century Park East
Los Angeles, CA 90067
Founded in 2004
Key Executives for Ritter Pharmaceuticals, Inc.
Ritter Pharmaceuticals, Inc. does not have any Key Executives recorded.
Ritter Pharmaceuticals, Inc. Key Developments
Ritter Pharmaceuticals, Inc. Announces Resignation of Jeffrey Benjamin as Vice President, Finance
Apr 13 18
Ritter Pharmaceuticals, Inc. announced that on and effective as of April 9, 2018, Jeffrey Benjamin resigned as Vice President, Finance of the company. The Company has commenced a search for Mr. Benjamin's replacement and has retained a financial consultant to assist the Company during the transition period until a replacement for Mr. Benjamin is identified.
Ritter Pharmaceuticals, Inc. Amends and Restates Certificate of Incorporation
Mar 22 18
Ritter Pharmaceuticals, Inc. filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware to effect a 1-for-10 reverse stock split of the Company’s issued and outstanding common stock, par value $0.001 per share effective March 23, 2018. The Amendment provides that on the Effective Date, every ten shares of the Company’s issued and outstanding Common Stock immediately prior to the Effective Date, shall automatically be reclassified, without any action on the part of the holder thereof, into one share of Common Stock. No fractional shares will be issued as a result of the Reverse Stock Split. Stockholders who otherwise would be entitled to receive a fractional share in connection with the Reverse Stock Split will receive a cash payment in lieu thereof.
Ritter Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Year Ended December 31, 2017
Mar 19 18
Ritter Pharmaceuticals, Inc. reported earnings results for the fourth quarter and year ended December 31, 2017. For the quarter the company reported net loss attributable to common stockholders of approximately $5.1 million compared to a net loss of approximately $7.6 million for the fourth quarter of 2016. Basic and diluted net loss per share was $0.11 for the three months ended December 31, 2017 compared to basic and diluted net loss per share of $0.74 for the same period in 2016.
For the year the company reported a net loss attributable to common stockholders of approximately $11.0 million compared to a net loss of approximately $18.4 million for the year ended December 31, 2016. Basic and diluted net loss per share was approximately $0.50 for the year ended December 31, 2017 compared to basic and diluted net loss per share of approximately $2.04 for the same period in 2016. As of December 31, 2017, company had cash and cash equivalents of approximately $22.6 million.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|